Biopharmaceutical company Oakrum Pharma LLC revealed on Monday the launch of an agreement to develop and manufacture two prescription generic pharmaceutical products to be commercialised in the US under the Oakrum label.
The company said it has signed the product development and commercialisation partnership with Biophore India Pharmaceuticals Pvt Ltd, a pharmaceutical company.
Both the prescription generic pharmaceutical products are expected to be sold through the specialty distribution market channel.
For the 12-month period ending 31 December 2018, the total market for the products in the US exceeded USD150m in aggregate sales, according to Bloomberg data.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval